At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 51 enrolled
Drug / intervention
Gefapixant +1 moredrug
Likely dose
Gefapixant 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)·interventional·Posted Jul 20, 2015·Updated May 26, 2021
In Brief
A Phase 2 clinical trial evaluating Gefapixant and Placebo for Idiopathic Pulmonary Fibrosis and Cough. Completed, enrolled 51 participants.
Detailed Summary
A randomized, double-blind, placebo-controlled, crossover, dose escalation study of gefapixant (AF-219) in participants with Idiopathic Pulmonary Fibrosis (IPF) with persistent cough.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Pulmonary Fibrosis, Cough
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 2015
Enrollment StartAug 2015
Primary CompletionJul 2016
Study CompletionJul 2016
TodayJul 2026
First PostedJul 20, 2015
Enrollment StartAug 26, 2015
Primary CompletionJul 1, 2016
Study CompletionJul 14, 2016
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 11.0 years ago
Interventions
Gefapixantdrug
Gefapixant 50 mg tablet, administered by mouth
Placeboother
Matching placebo to gefapixant, tablet administered by mouth